Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 2016

View Archived Issues

Alpine Immune Sciences announces USD 48 million series A financing

EnBiotix signs deal with Mayo Clinic to continue development of EPP-001

Regen BioPharma identifies small molecules that activate NR2F6

Marathon Pharmaceuticals submits NDA to FDA for deflazacort in DMD

Shire signs global rights agreement with Pfizer for PF-00547659

Promising activity seen in colorectal cancer study with encorafenib, cetuximab and alpelisib

Janssen BACE inhibitor studied for Alzheimer's in asymptomatic subjects

Novartis patents complement factor D inhibitors

The Medicines Company doses first patient in phase II trial of ABP-700

PharmaMar starts trial for plitidepsin in patients with T-cell lymphoma

GlaxoSmithKline discloses CD38 inhibitors

Merck & Co. describes BACE 1/2 inhibitors

Takeda Pharmaceutical develops ACC1 inhibitors

Advanced Proteome Therapeutics annnounces partnership with Heidelberg Pharma

New ADC IMGN-632 shows promising preclinical results in AML

Phase I/II study finds encouraging survival with VAL-083 in recurrent glioblastoma

[18F]FTP2, a novel PET probe to detect gefitinib-resistant tumors

PRX-003: first-in-human data

Sirukumab: data from SIRROUND-D

twoXAR completes preclinical studies to evaluate rheumatoid arthritis candidates

Topline results from phase II study of duvelisib in refractory indolent NHL

Mesoblast regains rights to mesenchymal precursor cell technology platform

Vicore completes first-in-human study of C-21

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...